The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).

Martina FrodlundPer NivedKaterina ChatzidionysiouAnna SödergrenEva KlingbergMonica HanssonSophie OhlssonElisa PinAnders BengtssonLars KlareskogMeliha Crnkic Kapetanovic

Published in: Microbiology spectrum (2024)

EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) with number 2021-000880-63.

Keyphrases

coronavirus disease
sars cov
clinical trial
rheumatoid arthritis
adverse drug
oxidative stress
respiratory syndrome coronavirus
cancer therapy
emergency department
open label
drug delivery
electronic health record